Jci_page_head_homepage_01 Jci_page_head_homepage_02
Pranavkumar Shivakumar, Gregg E. Sabla, Peter Whitington, Claire A. Chougnet, Jorge A. Bezerra
Published in Volume 119, Issue 8
J Clin Invest. 2009; 119(8):2281–2290 doi:10.1172/JCI38879
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 10
Improved outcome after blocking Nkg2d.

(A) Development of symptoms, weight gain, and survival after daily i.p. injections of 100 μg of anti-Nkg2d neutralizing antibodies (or IgG isotype control) into neonatal mice injected with saline or RRV on the first day of life. Saline, Nkg2d Ab: n = 8; RRV, Nkg2d Ab: n = 38; RRV, control IgG: n = 13. *P < 0.01. (B) H&E staining of representative longitudinal sections of murine extrahepatic bile ducts at different time points after injection of RRV on the first day of life, followed by the daily administration of 100 μg of blocking anti-Nkg2d antibodies. Scale bars: 50 μm.